C18 Ceramide-d3 (d18:1/18:0) is intended for use as an internal standard for the quantification of C18 Ceramide (d18:1/18:0) by GC- or LC-MS. C18 Ceramide is an endogenous bioactive sphingolipid. It is the primary short-chain ceramide found in brain tissue whose synthesis is regulated by longevity-assurance homologue 1 (Lass1) in mice.1 Increased expression of C18 ceramide reduces cell growth in UM-SCC-22A squamous cell carcinoma cells.2 It is selectively downregulated in 32 human head and neck squamous cell carcinoma tumor tissues as compared to non-squamous tumor tissues. C18 Ceramide concentration is significantly higher in muscle tissue of type 2 diabetic patients compared with non-diabetic patients and is positively correlated to body mass index and inversely related to insulin sensitivity.3 [Matreya, LLC. Catalog No. 2201]
1.Mizutani, Y., Kihara, A., and Igarashi, Y.Mammalian Lass6 and its related family members regulate synthesis of specific ceramidesBiochem J.390(Pt. 1)263-271(2005)
2.Koybasi, S., Senkal, C.E., Sundararaj, K., et al.Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomasJ. Biol. Chem.279(43)44311-44319(2004)
3.Bergman, B.C., Brozinick, J.T., Strauss, A., et al.Muscle sphingolipids during rest and exercise: A C18:0 signature for insulin resistance in humansDiabetologia59(3)785-791(2016)
